Sho Wakamatsu, Teruo Jojima, Masaaki Hashiguchi, Haruka Kishi, Takafumi Niitani, Shintaro Sakurai, Toshie Iijima, Takahiko Kogai, Takuya Tomaru, Isao Usui, Yoshimasa Aso
Non-alcoholic fatty liver disease (NAFLD) is increasing globally, and seeking therapeutic molecule targets is urgent. Several studies have demonstrated that IL-33 plays an important role in the progression of Non-alcoholic steatohepatitis (NASH) with fibrosis and the proliferation of hepatocellular carcinoma (HCC). However, whether the inhibition of IL-33 signaling prevents NAFLD from progressing to NASH and HCC has not been clarified. We investigated the effects of a novel antibody, IL-33RAb, and luseogliflozin, a SGLT2 inhibitor, when administered to a model mouse for NASH and HCC, and their effects were compared to investigate the mechanisms of how IL-33 is involved in the pathogenesis of NASH progression...
November 23, 2023: Journal of Diabetes and its Complications